Skip to main content
Equibles

LOTUSEYE · Lotus Eye Hospital and Institute Limited · Financials

Use LOTUSEYE with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research LOTUSEYE.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
103.03 INR -0.04 (-0.04%) At close · Nov 13
Rebalance outlook locked
Market Cap
2.14B INR
Shares
20.80M
Volume · Nov 13 59.68K Avg daily vol (3M) 17.38K

Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.

Pull these statements through the financial statements API or MCP →
Revenue
537.14M +8.4%
FY2026 Revenue FY2019–FY2026
Net Income
804K -89.1%
FY2026 Net Income FY2019–FY2026
Operating Cash Flow
31.38M -36.6%
FY2026 Operating Cash Flow FY2022–FY2026

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item TTM FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
INR 619.4M 537.14M 495.63M 482.1M 470.44M 389.1M 323.69M 405.53M 384.25M
INR 54.2M 37.49M 30.07M 37.28M 29.81M 25.01M 23.3M 24.97M 30.59M
INR 17.16M 8.59M 3.55M 974K 976K 1.28M 649K 705K 644K
INR 7.13M -536K 13.83M 40.14M 56.52M 40.94M 19.92M 14.56M 6.28M
INR 2.4M -1.34M 6.43M 10.99M 15.75M 11.09M 4.25M 3.91M -802K
INR 4.73M 804K 7.39M 29.15M 40.78M 29.84M 15.67M 10.65M 0
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2026: 31.36M in dividends.

Debt Profile

No verified debt profile is available yet. This does not establish that the company has no debt or covenants.